Russian CRO acquires clinical research company in Argentina
This article was originally published in Scrip
Executive Summary
The St Petersburg-based contract drug development company PSI has completed the acquisition of Thywill, a CRO headquartered in Buenos Aires, Argentina. Thywill specialises in clinical trials management across Latin America, and PSI hopes to benefit from this experience and expand its operations in Argentina, Peru, Ecuador, Uruguay, Colombia, Chile and Mexico. In addition to Russia and other ex-Soviet republics, PSI operates across Europe, and in North and South Americas. It employs more than 200 people in 22 countries who have experience in multinational regulatory issues relating to clinical research. In the 15 years passed since its establishment, the company completed more than 300 studies in all major therapeutic areas and more than 400 sponsor audits.